Literature DB >> 7603571

CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells.

J C Rathmell1, M P Cooke, W Y Ho, J Grein, S E Townsend, M M Davis, C C Goodnow.   

Abstract

The recessive mouse mutations lpr and gld create deficiencies in an interacting pair of cell surface molecules, CD95 (Fas/APO-1) and Fas-ligand (FasL), respectively, resulting in autoantibody production resembling human systemic lupus erythematosus. The mechanisms of self-tolerance affected by deficiency in either molecule are not established, but CD95 deficiency both in B cells and in CD4+ T cells recognizing major histocompatibility complex (MHC) class II molecules is required for autoimmunity in lpr mice. Here we track the outcome of in vivo interactions between B cells and CD4+ T cells that recognize a transgene-encoded autoantigen, hen egg lysozyme (HEL), using cells from mice transgenic for immunoglobulin and T-cell receptor (TCR) genes. B cells that had not previously encountered HEL autoantigen (naive cells) were triggered into proliferation and antibody production upon interaction with antigen and HEL-specific CD4+ T cells. By contrast, B cells that had been chronically exposed to HEL during their development and carried desensitized surface immunoglobulin (sIg) antigen receptors (anergic cells) did not produce antibody but instead were eliminated in the presence of HEL-specific CD4+ T cells. CD95-deficient anergic B cells, however, were not eliminated by CD4+ T cells and were triggered to proliferate. These findings identify a novel regulatory step for eliminating autoreactive B cells that seems unique in its dependence on CD95.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603571     DOI: 10.1038/376181a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  107 in total

1.  Immature B lymphocytes from adult bone marrow exhibit a selective defect in induced hyperexpression of major histocompatibility complex class II and fail to show B7.2 induction.

Authors:  S Marshall-Clarke; L Tasker; R M Parkhouse
Journal:  Immunology       Date:  2000-06       Impact factor: 7.397

Review 2.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

3.  Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis.

Authors:  Elaine J Schattner; Steven M Friedman; Paolo Casali
Journal:  Autoimmunity       Date:  2002-07       Impact factor: 2.815

Review 4.  The regulation and activation potential of autoreactive B cells.

Authors:  Michele L Fields; Su-Jean Seo; Simone A Nish; Jeff H Tsai; Andrew J Caton; Jan Erikson
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 5.  Antigen-specific responses in autoimmunity and tolerance.

Authors:  J W Thomas
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 6.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

7.  Precursor B cells for autoantibody production in genomically Fas-intact autoimmune disease are not subject to Fas-mediated immune elimination.

Authors:  S Hirose; K Yan; M Abe; Y Jiang; Y Hamano; H Tsurui; T Shirai
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

8.  The ups and downs of negative (and positive) selection of B cells.

Authors:  Jean-Claude Weill; Claude-Agnès Reynaud
Journal:  J Clin Invest       Date:  2015-09-14       Impact factor: 14.808

9.  Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.

Authors:  S Mihara; N Suzuki; Y Takeba; K Soejima; S Yamamoto
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 10.  The many roles of FAS receptor signaling in the immune system.

Authors:  Andreas Strasser; Philipp J Jost; Shigekazu Nagata
Journal:  Immunity       Date:  2009-02-20       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.